Tafinlar (Dabrafenib) Capsules
Generic name : Dabrafenib.
Trade name : Tafinlar.
Manufacturer information :
Tafinlar is manufactured by Glaxo Smith Kline.
Tafinlar FDA Approval :
Tafinlar first approved May 29th, 2013.
Tafinlar Dosage form:
Capsules: 50 mg, 75 mg.
Tafinlar Indications and Usag e:
BRAF protein kinase inhibitor indicated as a single agent for unresectable or metastatic melanoma with BRAF V600E mutation, or in combination with trametinib for BRAF V600E or V600K mutations.
Tafinlar (Dabrafenib) availability in India
- You could import this medicine against import permit on Patient Name.
- Please contact ACT Lifesciences Private Limited for further information.